TB Alliance manages the largest pipeline of new TB drugs in history.
The Director, Market Access will be responsible for implementation of market interventions, contributing to rapid introduction, and broad access to novel TB regimens in low- and middle-income countries especially those with high incidence of tuberculosis.
The position is broad in scope, with interventions at global, regional and country level, in collaboration with technical, global health and commercial partners, and will play a pivotal role in creating global access to TB Alliance developed regimens.
The Market Access function at the TB Alliance includes all elements on the value chain including supplier relationship management, pricing strategy, forecasting, market understanding, resource mobilization, support for policy change, regulatory issues, diagnostics as well as technical adoption-related issues.
The opening is happening at an exciting time for new TB regimens. Regulatory approval for a novel, short, all-oral regimen for XDR-TB has recently been obtained, and work is ongoing to support planning for a forthcoming short regimen for both DS and MDR-TB.
TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster, affordable tuberculosis drugs that are available to those who need them.Through innovative science and with partners around the globe, we lead a global effort to ensure development of and equitable access to faster, better tuberculosis cures that will advance global health and prosperity.
With an annual operating budget of approximately $60 million, the TB Alliance leads the advancement of the most comprehensive R&D portfolio of TB drug candidates in history. Additionally, the TB Alliance drives efforts to ensure regulatory approval, country adoption of new regimens, and widespread availability of new drug regimens to patients. For more information, please access the website: www.tballiance.org.